New Medical Articles 11/27
Posted by rob on November 27, 2006 under Uncategorized | 
Be the First to Comment
Medical Articles 11/16
Posted by rob on November 17, 2006 under Uncategorized | Be the First to Comment
Medical Articles Today 11/7/2006
Posted by rob on November 7, 2006 under Uncategorized | Read the First Comment
Modelling Hematopoiesis Mediated by Growth Factors With Applications to Periodic Hematological Diseases.
Biological inhibitory effects of the chinese herb danggui on brain astrocytoma.
Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib.
Cancer testis/germline antigens (CT/CG-antigens) in leukemias.
New CML Articles 11/1
Posted by rob on November 2, 2006 under Uncategorized | Read the First Comment
Myelodysplastic syndrome associated with monosomy 7 in childhood: a retrospective study.
A case of acute myelogenous leukemia with MLL-AF10 fusion caused by insertion of 5′MLL into 10p12, with concurrent 3′MLL deletion.
[The expression and clinical significance of survivin gene in leukemia]
Radioimmunotherapy of non-Hodgkin’s lymphomas.
Expression analysis of PCNA gene in chronic myelogenous leukemia-Combined application of siRNA silencing and expression arrays.
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR/ABL+ leukemias.
Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Allele-Specific Polymerase Chain Reaction for the Imatinib-Resistant KIT D816V and D816F Mutations in Mastocytosis and Acute Myelogenous Leukemia.
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Emerging drugs in chronic myelogenous leukaemia.
New potential targets for treating myeloma bone disease.
Effects of Histamine on Immunophenotype and Notch Signaling in Human HL-60 Leukemia Cells.
Podocalyxin is expressed in normal and leukemic monocytes.
Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.
Bloodlines – the importance of mentoring for the future of hematology.
Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype.
Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease.
Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology.
Fasciitis after allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia.
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.
Resistant Microascus cirrosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor.
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,2′-bipyridine.
Evaluation of anticancer activity of 4-vinyl-1-arylsulfonylimidazolidinones.
Acute fulminant myocarditis after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning for acute myelogenous leukemia.
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Paraplegia as the presenting manifestation of extramedullary megakaryoblastic transformation of previously undiagnosed chronic myelogenous leukemia.
Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.
Immunotherapeutic and immunoregulatory drugs in haematologic malignancies.
Acute myelogenous leukemia with monosomy 7 in a Hiroshima survivor 60 years after the atomic bomb.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia.
Selective binding of imatinib to the genetic variants of human alpha(1)-acid glycoprotein.
Social support and survival in patients with acute myeloid leukaemia.
A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation.
Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.
Donor leukocyte infusions in myeloid malignancies: new strategies.
Acute myelogenous leukemia associated with Ollier disease.
Alloreaction increases or restores CD40, CD54, and/or HLA molecule expression in acute myelogenous leukemia blasts, through secretion of inflammatory cytokines: dominant role for TNFbeta, in concert with IFNgamma.
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Can leukemia-derived dendritic cells generate antileukemia immunity?
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
Osteopenia and male hypogonadism.
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Antiangiogenic activity of 4′-thio-beta-D-arabinofuranosylcytosine.
An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions.
Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia.
Isodicentric Philadelphia chromosome in acute lymphoblastic leukemia with der(7;12)(q10;q10).
The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells.
Childhood acute myelogenous leukaemia: Association between PRAME, apoptosis- and MDR-related gene expression.
PU.1: An ETS family transcription factor that regulates leukemogenesis besides normal hematopoiesis.
Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow.
Myelofibrosis in chronic myeloproliferative disorders–dynamics and clinical impact.
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years.
Molecular medicine, the Medicare drug benefit, and the need for cost control.
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.
Treatment of acute myelogenous leukemia with outpatient azacitidine.
Determination of daunomycin in human plasma and urine by using an interference-free analysis of excitation-emission matrix fluorescence data with second-order calibration.
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
[Prognostic factor analysis of 77 old patients with acute myelogenous leukemia]
An update on the etiology and diagnostic evaluation of a leukemoid reaction.
Dasatinib in chronic myelogenous leukemia.
Dasatinib in chronic myelogenous leukemia.
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines.
Gene therapy for BCR-ABL(+) human CML with dual phosphorylation resistant p27(Kip1) and stable RNA interference using an EBV vector.
High-Dose celecoxib and metronomic “low-dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin’s lymphoma.
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Application of high throughput cell array technology to FISH: Investigation of the role of deletion of p16 gene in leukemias.
Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient.
Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.
Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia.
Mucormycosis resulting in gastric perforation in a patient with acute myelogenous leukemia: report of a case.
Polymyositis complicating donor lymphocyte infusion after stem cell transplantation for relapsed chronic myeloid leukemia: report of a case and review of literature.
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
Chronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapies.
Granular acute lymphoblastic leukemia in adults: report of a case and review of the literature.
Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
Pharmacokinetic considerations in the treatment of CNS tumours.
Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure.
Bilateral exudative retinal detachment as the first sign of relapsing acute myelogenous leukaemia.
[Detection of bcr/abl fusion gene from K562 cell line and mononuclear cells of CML patients by DNA-PCR]
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors.
Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.
Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts.
Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells.
Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.
Deletion of chromosome 13: A rare form of cytogenetic evolution in blast phase of chronic myelogenous leukemia Is there an association with favorable outcome?
Differentiation therapy as an effective strategy for the treatment of chronic myelogenous leukemia.
Human terminal deoxynucleotidyl transferases as novel targets for anticancer chemotherapy.
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.